Key Laboratory of Cell Proliferation and Differentiation of Ministry of Education, State Key Laboratory of Protein and Plant Gene Research, School of Life Sciences, Peking University, Beijing, 100871, China.
Peking-Tsinghua Center for Life Sciences, Peking University, Beijing, 100871, China.
Sci China Life Sci. 2017 Jun;60(6):563-574. doi: 10.1007/s11427-016-9066-0. Epub 2017 May 29.
While STING (STimulator of INterferon Genes) has been shown to be essential for cytosolic DNA-triggered innate immune activation, accumulated evidence obtained from various studies suggested that an intrinsic relevance of STING-associated signaling in tumorigenesis can be observed. Also, several clinical trials using immunostimulatory adjuvants, particularly agonistic as well as non-agonistic ligands for STING, have revealed their therapeutic potential not only as vaccine adjuvants but also as anti-tumor agents. However, cases have also been reported where the involvement of STING shows a protective role in tumor growth. Here we summarize recent findings that have pointed towards the STING pathway as an innate immune sensing mechanism driving type I interferon production in the tumor context. Better understanding of this pathway can guide further development of novel immunotherapeutic strategies in the treatment of cancer.
虽然 STING（干扰素基因刺激物）已被证明对于细胞质 DNA 触发的先天免疫激活是必不可少的，但来自各种研究的累积证据表明，STING 相关信号在肿瘤发生中的内在相关性是可以观察到的。此外，几项使用免疫刺激佐剂的临床试验，特别是针对 STING 的激动剂和非激动剂配体，已经揭示了它们不仅作为疫苗佐剂，而且作为抗肿瘤药物的治疗潜力。然而，也有报道称，STING 的参与在肿瘤生长中起到了保护作用。在这里，我们总结了最近的发现，这些发现指出 STING 途径是驱动肿瘤环境中 I 型干扰素产生的先天免疫感应机制。更好地了解这一途径可以指导在癌症治疗中开发新的免疫治疗策略。
